ERBB2 and breast cancer: In routine clinical practice, however, relying on immunohistochemical analysis of the estrogen receptor (ER), progesterone receptor and her2/neu receptor, breast cancer is subdivided into hormone receptor positive, her2/neu receptor positive, and (lack of all three receptors) triple negative [6].